The Bundibugyo Ebola outbreak centred on the Democratic Republic of the Congo has now killed 5,376 people, according to Africa CDC. That makes it one of the deadliest Ebola epidemics ever recorded. From tonight, every traveller flying to the United States must declare that they have not been in the DRC in the previous 21 days. No licensed vaccine or treatment exists for this species of the virus.
The numbers continue to climb. On Monday, Africa CDC told Agence France-Presse that the outbreak had caused 5,376 deaths: 5,372 in the Democratic Republic of the Congo, two in Kenya and two in Uganda. Confirmed cases exceed 10,000. Among them, more than half of those infected have died, according to DRC data to 31 October.
Those figures are not directly comparable with the US Centers for Disease Control and Prevention’s count of 10,305 confirmed cases and 4,996 deaths as of 28 October, cited in NSH’s 31 October and 2 November editions. Agencies count suspected, probable and confirmed cases differently and update on different days. The direction is not in doubt.
Why Bundibugyo is different
Ebola disease is caused by several related viruses. The most familiar, Zaire ebolavirus, caused the 2014–16 West African epidemic that killed more than 11,000 people. Over the following decade it became partly controllable, thanks to the Ervebo vaccine and two antibody treatments. None of those tools is licensed for Bundibugyo virus, the species behind this outbreak. Previous Bundibugyo outbreaks, in Uganda in 2007 and the DRC in 2012, were far smaller.
Candidate vaccines are in trials, including Ervebo (tested for cross-protection), Moderna’s mRNA-1469 and an Oxford ChAdOx1-based vaccine. On 28 October, the US Biomedical Advanced Research and Development Authority (BARDA) awarded $36 million to a consortium led by IAVI to advance a candidate. These are steps towards a tool, not yet a tool. Control still depends on the classic measures: finding cases fast, isolating them, tracing contacts, safe burials and protecting health workers.
The US rule
From 23:59 US Eastern Time on 3 November (10:29 IST on 4 November), every air traveller bound for the United States, including US citizens, must attest that they have not been in the DRC within the previous 21 days, the maximum incubation period. The CDC order, issued on 22 October and amended on 28 October, runs until 18 December. Airlines for America and the International Air Transport Association (IATA) have both objected. They argue that blanket attestation burdens airlines and passengers while adding little protection compared with targeted screening.
Kenya has separately criticised Saudi Arabia’s travel ban as “excessive”, as NSH reported yesterday. The WHO’s International Health Regulations generally discourage travel bans, partly because they can deter countries from reporting outbreaks quickly.
Why it matters for India
India declared no new measures in the window. The relevant links are practical rather than alarming:
- Travel:Indian travellers and returning workers from East and Central Africa pass through airport health screening and self-declaration systems such as Air Suvidha.
- Peacekeepers: Indian peacekeepers have long served in the UN mission in the DRC.
- Medicines and diagnostics: Indian vaccine and diagnostics manufacturers are potential partners in any scale-up once a candidate succeeds.
The risk of Ebola reaching India remains low. The disease spreads through direct contact with the body fluids of symptomatic patients, not through the air, and India’s surveillance and isolation capacity was strengthened after 2014.
– Rithvisha Kiran
